VIFOR (INTERNATIONAL) LTD.
VIFOR (INTERNATIONAL) LTD. reported $202.0K in payments to physicians and teaching hospitals across 31 transactions in CMS Open Payments PY 2024.
Pharmaceutical payment transparency data for VIFOR (INTERNATIONAL) LTD.. Ranked #931 of 1,797 companies by total payments. Source: CMS Open Payments, Program Year 2024.
Payment Overview
Total Payments
$202.0K
0.0% of all payments
Transactions
31
$6.5K avg
Recipients
30
$6.7K avg
Industry Rank
#931
of 1,797 companies
What the Data Shows for VIFOR (INTERNATIONAL) LTD.
In Program Year 2024, VIFOR (INTERNATIONAL) LTD. reported $202,010.66 in payments to 30 physicians and teaching hospitals across 31 individual transactions — an average of $6.5K per transaction and $6.7K per recipient. That total places VIFOR (INTERNATIONAL) LTD. at rank #931 out of 1,797 companies in the CMS Open Payments database, representing 0.0% of all industry payments reported nationwide for the year. Payment volume at this scale is characteristic of manufacturers with broad prescriber engagement, active clinical research programs, or patented therapies generating ongoing royalty obligations.
The payment mix for VIFOR (INTERNATIONAL) LTD. spans 2 distinct categories defined by CMS — including general payments (consulting, speaker fees, meals, travel), research payments tied to clinical trials, and ownership or investment interests. The largest single category is "Consulting Fee" at $131.9K, accounting for 65.3% of the company's reported total and 29 transactions. This distribution matters because different payment types carry different regulatory and ethical implications: research funding supports clinical development, while general payments like meals and speaker fees have been studied for their correlation with prescribing patterns in peer-reviewed journals such as JAMA Internal Medicine.
Recipient concentration is another useful lens. The top 5 recipients of payments from VIFOR (INTERNATIONAL) LTD. received $0.00 combined — 0.0% of the company's total — with the remaining 100.0% distributed across the rest of the 30 recipients. A relatively distributed top-5 share suggests broader engagement across the prescriber community rather than concentration among a handful of high-value relationships. All figures above are drawn directly from the CMS Open Payments Public Use Files for PY2024 and are disclosed under the Physician Payments Sunshine Act; this page summarizes reported financial transfers and does not represent medical advice or judgment about individual prescribing decisions.
Payment Breakdown by Type
VIFOR (INTERNATIONAL) LTD. made 2 types of payments. "Consulting Fee" accounts for 65.3%.
65.3% · 29 transactions
0.0% · 1 transactions
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $131.9K | 29 | 65.3% |
| Travel and Lodging | $101.00 | 1 | 0.0% |
Payment Size Analysis
Average transaction size: $6.5K. Average per recipient: $6.7K.
Total Amount
$202,010.66
Avg per Transaction
$6.5K
Avg per Recipient
$6.7K
Payment Transparency Context
The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.
Industry Total (2024)
$13.3B
across 1,797 companies
VIFOR (INTERNATIONAL) LTD. Share
0.0%
#931 by total payments
Related Healthcare Data
Explore related drug and healthcare provider data from other federal sources
PlainMeds — Drug Information
FDA drug data for 682 medications including interactions and alternatives. Look up drugs that VIFOR (INTERNATIONAL) LTD. may manufacture.
PlainDoctor — Provider Data
CMS provider data for 7M+ healthcare providers. Search for physicians who may be recipients of pharmaceutical payments.
PlainHospital — Hospital Quality
CMS Hospital Compare data for 5,400+ hospitals. View quality ratings for teaching hospitals that receive pharmaceutical payments.
PlainRecalls — FDA Recalls
FDA drug and device recall data. Check recall history for products manufactured by VIFOR (INTERNATIONAL) LTD..
PlainProcedure — Procedure Costs
Medicare procedure cost data for 9,200+ procedures. See what hospitals charge for medical procedures and how costs vary by state.
Learn More About Pharma Payments
In-depth guides on pharmaceutical industry payment transparency
Understanding Open Payments
How the Sunshine Act works and what payment data means for patients and physicians.
Drug Company Marketing Practices
How pharmaceutical companies market to healthcare professionals and why it matters.
Pharma Payment Types Explained
A guide to the different types of payments pharmaceutical companies make to physicians.
Companies with Similar Payment Volumes
Pharmaceutical companies with payment totals similar to VIFOR (INTERNATIONAL) LTD.
Frequently Asked Questions
How much did VIFOR (INTERNATIONAL) LTD. pay to physicians and hospitals in 2024? ▾
How many physicians received payments from VIFOR (INTERNATIONAL) LTD.? ▾
What types of payments did VIFOR (INTERNATIONAL) LTD. make? ▾
How does VIFOR (INTERNATIONAL) LTD. rank among pharmaceutical companies? ▾
What is the average payment size from VIFOR (INTERNATIONAL) LTD.? ▾
Are the top recipients concentrated for VIFOR (INTERNATIONAL) LTD.? ▾
Where does the payment data for VIFOR (INTERNATIONAL) LTD. come from? ▾
Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.3B across 1,797 companies.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
